Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Mosquitos are eating us alive into October; I just annihilated an Aedes albopictus that was supping on my shoulder. Is there a Kalshi market for wagers on when dengue will hit SoCal?
The need-to-know this morning
- Novartis is paying $575 million upfront to license an experimental mRNA-based autoimmune therapy from the Chinese firm Abogen Biosciences, the latest case of a large pharma company looking to China to restock its pipeline.
NIH dollars are flowing, but uncertainty persists
The National Institutes of Health spent the $34 billion it was allocated by Congress for research grants in the 2026 fiscal year, but a slower and increasingly opaque funding process is now making it harder to actually do science, a STAT analysis shows.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
